The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction
Open accessAbstract
Aerobic glycolysis regulates T cell function. However, whether and how primary cancer alters T cell glycolytic metabolism and affects tumor immunity in cancer patients remains a question. Here we found that ovarian cancers imposed glucose restriction on T cells and dampened their function via maintaining high expression of microRNAs miR-101 and miR-26a, which constrained expression of the methyltransferase EZH2. EZH2 activated the Notch pathway by suppressing Notch repressors Numb and Fbxw7 via trimethylation of histone H3 at Lys27 and, consequently, stimulated T cell polyfunctional cytokine expression and promoted their survival via Bcl-2 signaling. Moreover, small hairpin RNA-mediated knockdown of human EZH2 in T cells elicited poor antitumor immunity. EZH2(+)CD8(+) T cells were associated with improved survival in patients. Together, these data unveil a metabolic target and mechanism of cancer immune evasion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“short hairpin RNAs (shRNAs) targeting EZH2 compromise the ability of CD8 + CTLs to mount robust immune responses”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Zhao et al., 2016
In the citing paper
“correlating with a positive prognostic impact for tumor infiltration by EHZ2 + CD8 + cells in patients with ovarian cancer”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Zhao et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & PEPE, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,870
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Self-citationThe Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
Cited by
Sorted by citations
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Self-citationChemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.49 · Cited by 2,251
Self-citationPitt, J. M., Marabelle, A., Eggermont, A. M. M., Soria, J., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,355
Metabolic Instruction of Immunity
Buck, M. D., Sowell, R., Kaech, S. M., & Pearce, E. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.004 · Cited by 1,270
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169
Self-citationEZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 980
Metabolism of immune cells in cancer
Leone, R. D., & Powell, J. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0273-y · Cited by 877
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
Unraveling the Complex Interplay Between T Cell Metabolism and Function
Geltink, R. I. K., Kyle, R. L., & Pearce, E. L. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053019 · Cited by 849
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Self-citationScharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 708
Cancer SLC43A2 alters T cell methionine metabolism and histone methylation
Bian, Y., Li, W., Kremer, D. M., Sajjakulnukit, P., Li, S., Crespo, J., Nwosu, Z. C., Zhang, L., Czerwonka, A., Pawłowska, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2682-1 · Cited by 660
Self-citationTargeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 665
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A.-T., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 630
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P., & Verdeil, G. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.80 · Cited by 570
FBXW7: a critical tumor suppressor of human cancers
Yeh, C., Bellon, M., & Nicot, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0857-2 · Cited by 525
Epigenetic control of CD8+ T cell differentiation
Henning, A. N., Roychoudhuri, R., & Restifo, N. P. (2018) · Nature reviews. Immunology · doi:10.1038/nri.2017.146 · Cited by 518
Reversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Fates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
Self-citationLi, W., Tanikawa, T., Kryczek, I., Xia, H., Li, G., Wu, K., Wei, S., Zhao, L., Vatan, L., Wen, B., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.022 · Cited by 451
Self-citationGan, L., Yang, Y., Li, Q., Feng, Y., Liu, T., & Guo, W.-J. (2018) · Biomarker Research · doi:10.1186/s40364-018-0122-2 · Cited by 440
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 422
Self-citationThe spectrum of T cell metabolism in health and disease
Bantug, G. R., Galluzzi, L., Kroemer, G., & Hess, C. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.99 · Cited by 436
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 428
Self-citationEpigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W. T., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 412
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 419
Self-citationSiska, P. J., Beckermann, K. E., Mason, F. M., Andrejeva, G., Greenplate, A. R., Sendor, A. B., Chiang, Y.-C. J., Corona, A. L., Gemta, L. F., Vincent, B. G., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93411 · Cited by 389
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385
“The most widely studied histone lysine methylation sites in T cells are histone 3 lysine 4 (H3K4), and H3K27.”
BackgroundInfluentialSelf-citationExhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
Zhao, Y., Shao, Q., & Peng, G. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0344-8 · Cited by 382
Cong, J., Wang, X., Zheng, X., Wang, D., Fu, B., Sun, R., Tian, Z., & Wei, H. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.021 · Cited by 387
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Jiang, X., Yin, T., & Lu, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 344
Self-citationThe tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
Lim, A. R., Rathmell, W. K., & Rathmell, J. C. (2020) · eLife · doi:10.7554/elife.55185 · Cited by 336
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Zingg, D., Arenas-Ramirez, N., Şahin, D., Rosalia, R. A., Antunes, A. T., Häusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 339
Immunometabolism of regulatory T cells
Newton, R. H., Priyadharshini, B., & Turka, L. A. (2016) · Nature Immunology · doi:10.1038/ni.3466 · Cited by 338
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., Guillebon, É. D., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S. M., & Tartour, É. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 330
Programmed Cell Death Tunes Tumor Immunity
Liu, J., Hong, M., Li, Y., Chen, D., Wu, Y., & Hu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847345 · Cited by 330
Metabolic interventions in the immune response to cancer
O’Sullivan, D., Sanin, D. E., Pearce, E. J., & Pearce, E. L. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0140-9 · Cited by 320
Metabolic adaptation of lymphocytes in immunity and disease
Chapman, N. M., & Chi, H. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.012 · Cited by 317
Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy
Liu, X., Hartman, C. L., Li, L., Albert, C. J., Si, F., Gao, A., Huang, L. J., Zhao, Y., Lin, W., Hsueh, E. C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6314 · Cited by 287
Li, C., Zhu, B., Son, Y. M., Wang, Z., Jiang, L., Xiang, M., Ye, Z., Beckermann, K. E., Wu, Y., Jenkins, J. W., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.013 · Cited by 251
Self-citationEZH2-Targeted Therapies in Cancer: Hype or a Reality
Eich, M., Athar, M., Ferguson, J. E., & Varambally, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2147 · Cited by 254
Self-citationKakaradov, B., Arsenio, J., Widjaja, C. E., He, Z., Aigner, S., Metz, P. J., Yu, B., Wehrens, E. J., Lopez, J. M., Kim, S. H., et al. (2017) · Nature Immunology · doi:10.1038/ni.3688 · Cited by 231
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
Cai, J., Wang, D., Zhang, G., & Guo, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221340 · Cited by 251
Wnt signaling pathway in cancer immunotherapy
Zhou, Y., Jiang, X., Luo, H., Meng, X., Chen, M., & Zhu, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.034 · Cited by 241
Metabolic Control of CD8+ T Cell Fate Decisions and Antitumor Immunity
Zhang, L., & Romero, P. J. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.11.005 · Cited by 241
Tissue-resident memory T cells in tumor immunity and immunotherapy
Okła, K., Färber, D. L., & Zou, W. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201605 · Cited by 239
Self-citationHuang, Y., Cai, K., Xu, P., Wang, L., Huang, C., Fang, Y., Cheng, S., Sun, X., Liu, F., Huang, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00437-8 · Cited by 231
Immunometabolism in systemic lupus erythematosus
Morel, L. M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.43 · Cited by 219
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
T‐cell metabolism governing activation, proliferation and differentiation; a modular view
Dimeloe, S., Burgener-Gasser, A.-V., Grählert, J., & Hess, C. (2016) · Immunology · doi:10.1111/imm.12655 · Cited by 202
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 210
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
Kouidhi, S., Ayed, F. B., & Elgaaïed, A. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00353 · Cited by 195
Huang, S., Wang, Z., Zhou, J., Huang, J., Zhou, L., Luo, J., Wan, Y. Y., Long, H., & Zhu, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2395 · Cited by 185
Self-citationNachef, M., Ali, A. K., Almutairi, S. M., & Lee, S.-H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624324 · Cited by 182
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Middelburg, J., Kemper, K., Engelberts, P. J., Labrijn, A. F., Schuurman, J., & van Hall, T. (2021) · Cancers · doi:10.3390/cancers13020287 · Cited by 178
Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression
Guo, L., Zhang, P., Chen, Z., Xia, H., Li, S., Zhang, Y., Kobberup, S., Zou, W., & Lin, J. D. (2017) · Journal of Clinical Investigation · doi:10.1172/jci96324 · Cited by 170
Self-citationThe Notch signaling pathway: a potential target for cancer immunotherapy
Li, X., Yan, X., Wang, Y., Kaur, B., Han, H., & Yu, J. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01439-z · Cited by 177
Self-citationFBXW7 in Cancer: What Has Been Unraveled Thus Far?
Sailo, B. L., Banik, K., Girisa, S., Bordoloi, D., Fan, L., Halim, C. E., Wang, H., Kumar, A. P., Zheng, D., Mao, X., et al. (2019) · Cancers · doi:10.3390/cancers11020246 · Cited by 168
Self-citationHuang, L., Xu, H., & Peng, G. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2018.4 · Cited by 170
Metabolism drives macrophage heterogeneity in the tumor microenvironment
Li, S., Yu, J., Huber, A. K., Kryczek, I., Wang, Z., Jiang, L., Li, X., Du, W., Li, G., Wei, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110609 · Cited by 179
Self-citationLiu, J., Bai, Y., Li, Y., Li, X., & Luo, K. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105301 · Cited by 170
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells
Stephen, T. L., Payne, K. K., Chaurio, R. A., Allegrezza, M. J., Zhu, H., Pérez‐Sanz, J., Perales‐Puchalt, A., Nguyen, J. M., Vara-Ailor, A., Eruslanov, E. B., et al. (2017) · Immunity · doi:10.1016/j.immuni.2016.12.015 · Cited by 164
Microenvironmental Metabolism Regulates Antitumor Immunity
Ngwa, V. M., Edwards, D. N., Philip, M., & Chen, J. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0617 · Cited by 156
Kumagai, S., Itahashi, K., & Nishikawa, H. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00870-6 · Cited by 171
Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target
Garnier, D., Renoult, O., Alves‐Guerra, M., Paris, F., & Pecqueur, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00118 · Cited by 161
Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells
Hamaidi, I., Zhang, L., Kim, N., Wang, M.-H., Iclozan, C., Fang, B., Liu, M., Koomen, J. M., Berglund, A., Yoder, S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.07.008 · Cited by 148
Xia, H., Wang, W., Crespo, J., Kryczek, I., Li, W., Wei, S., Bian, Z., Maj, T., He, M., Liu, J. R., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan4631 · Cited by 160
Self-citationImmune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Xu, H., Du, X., Xu, J., Zhang, Y., Tian, Y., Liu, G., Wang, X., Ma, M., Du, W., Liu, Y., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000603 · Cited by 149
Self-citationFbxw7 increases CCL2/7 in CX3CR1hi macrophages to promote intestinal inflammation
He, J., Song, Y., Li, G., Xiao, P., Liu, Y., Xue, Y., Cao, Q., Tu, X., Pan, T. S., Jiang, Z., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123374 · Cited by 146
Self-citationEpigenetic mechanisms regulating T-cell responses
Schmidl, C., Delacher, M., Huehn, J., & Feuerer, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.014 · Cited by 153
Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
Mardiana, S., Solomon, B., Darcy, P. K., & Beavis, P. A. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2293 · Cited by 140
Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease
Majumder, S., Thieme, K., Batchu, S. N., Alghamdi, T. A., Bowskill, B. B., Kabir, M. G., Liu, Y., Advani, S. L., White, K., Geldenhuys, L., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95946 · Cited by 125
Self-citationWei, F., Wang, D., Wei, J., Tang, N., Tang, L. M., Xiong, F., Guo, C. J., Zhou, M., Li, X., Li, G., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03581-0 · Cited by 128
Xia, H., Li, S., Li, X., Wang, W., Bian, Y., Wei, S., Grove, S., Wang, W., Vatan, L., Liu, J. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.141115 · Cited by 127
Self-citationTumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity
Scharping, N. E., & Delgoffe, G. M. (2016) · Vaccines · doi:10.3390/vaccines4040046 · Cited by 120
GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma
Sun, H.-W., Yu, X.-J., Wu, W., Chen, J., Shi, M., Zheng, L., & Xu, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168907 · Cited by 121
Zandberg, D. P., Menk, A. V., Velez, M., Normolle, D., DePeaux, K., Liu, A., Ferris, R. L., & Delgoffe, G. M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002088 · Cited by 119
CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
Gu, Y., Li, X., Bi, Y., Zheng, Y., Wang, J., Li, X., Huang, Z., Chen, L., Huang, Y., & Huang, Y. (2020) · Aging · doi:10.18632/aging.102656 · Cited by 119
Coit, P., Dozmorov, M. G., Merrill, J. T., McCune, W. J., Maksimowicz‐McKinnon, K., Wren, J. D., & Sawalha, A. H. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39720 · Cited by 119
Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy
Lian, X., Yang, K., Li, R., Li, M., Zuo, J., Zheng, B., Wang, W., Wang, P., & Zhou, S. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01486-5 · Cited by 120
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
Jones, B. A., Varambally, S., & Arend, R. C. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0437 · Cited by 118
Self-citationBeggars banquet: Metabolism in the tumor immune microenvironment and cancer therapy
Zou, W., & Green, D. R. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.003 · Cited by 122
Self-citationRegulation of CD8+ T Cells and Antitumor Immunity by Notch Signaling
Tsukumo, S., & Yasutomo, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00101 · Cited by 111
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 113
Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma
Tsou, P., Campbell, P. L., Amin, M. A., Coit, P., Miller, S. D., Fox, D. A., Khanna, D., & Sawalha, A. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813006116 · Cited by 109
Qorraj, M., Bruns, H., Böttcher, M., Weigand, L., Saul, D., Mackensen, A., Jitschin, R., & Mougiakakos, D. (2016) · Leukemia · doi:10.1038/leu.2016.214 · Cited by 108
Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
de Almeida, P. E., Mak, J., Hernandez, G., Jesudason, R., Hérault, A., Javinal, V., Borneo, J., Kim, J. M., & Walsh, K. B. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0360 · Cited by 103
LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
Liu, Y., Debo, B. M., Li, M., Shi, Z., Sheng, W., & Shi, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-27179-7 · Cited by 109
Self-citationRNA m 1 A methylation regulates glycolysis of cancer cells through modulating ATP5D
Wu, Y., Chen, Z., Xie, G., Zhang, H., Wang, Z., Zhou, J., Chen, F., Li, J., Chen, L., Niu, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119038119 · Cited by 104
Self-citationMetabolic reprograming of anti-tumor immunity
Sukumar, M., Kishton, R. J., & Restifo, N. P. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.03.011 · Cited by 103
Hua, S., Liu, C., Liu, L., & Wu, D. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.112 · Cited by 99
Metabolic regulation of immune responses: therapeutic opportunities
Aßmann, N., & Finlay, D. K. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83005 · Cited by 97
Epigenetic Control of the Tumor Microenvironment
Marks, D. L., Olson, R. L., & Fernández-Zapico, M. E. (2016) · Epigenomics · doi:10.2217/epi-2016-0110 · Cited by 93
Extracellular vesicles as antigen carriers for novel vaccination avenues
Mehanny, M., Lehr, C., & Fuhrmann, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.016 · Cited by 93
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
Kim, H. J., Cantor, H., & Cosmopoulos, K. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.08.010 · Cited by 88
Zhang, T., Xia, W., Song, X., Mao, Q., Huang, X., Chen, B., Liang, Y., Wang, H., Chen, Y., Yu, X., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01331-2 · Cited by 85
Self-citationJi, Y., Fioravanti, J., Zhu, W., Wang, H., Wu, T., Hu, J., Lacey, N. E., Gautam, S., Gall, J. B. L., Yang, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09882-8 · Cited by 88
Self-citation
Metadata
- Authors
- Zhao, E., Maj, T., Kryczek, I., Li, W., Wu, K., Zhao, L., Wei, S., Crespo, J., Wan, S., Vatan, L., Szeliga, W., Shao, I., Wang, Y., Liu, Y., Varambally, S., Chinnaiyan, A. M., Welling, T. H., Marquez, V., Kotarski, J., Wang, H., Wang, Z., Zhang, Y., Liu, R., Wang, G., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Wuhan Union Hospital (CN)
- Corresponding author
- Wang, Guobin
- Zou, Weiping
- ORCID
- Venue
- Nature Immunology
- Published
- 2015-11-02
- Volume
- 17
- Issue
- 1
- Pages
- 95-103
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- PMC
- PMC4684796
- OpenAlex
- W2202401513
- Cited by
- 405
- References
- 50
- Citations by year
- 2026: 19 · 2025: 30 · 2024: 37 · 2023: 35 · 2022: 54 · 2021: 51 · 2020: 42 · 2019: 34 · 2018: 38 · 2017: 35 · 2016: 29 · 2015: 1
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL127351)
- National Cancer Institute (R01CA092562, CA099985, R01CA123088, R01CA152470, R01CA156685, R01CA172106, CA123088, 5P30 CA 46592, CA156685, R01CA171306, R01CA193136, CA171306, R01CA099985, R01CA190176, P30CA046592)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor immune evasion, EZH2, microRNA, miR-101, miR-26a, glycolysis, glucose restriction, Notch signaling, H3K27me3, Numb, FBXW7, T cell apoptosis, ovarian cancer, antitumor immunity, CD8+ T cells
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Animals, Cell Separation, Female, Flow Cytometry, Fluorescent Antibody Technique, Glycolysis, Humans, Melanoma, Experimental, Mice, Inbred C57BL, Neoplasms, Ovarian Neoplasms, T-Lymphocytes, Transfection, Immunoblotting, Gene Expression Regulation, Neoplastic, Tumor Escape, MicroRNAs, Tissue Array Analysis, Chromatin Immunoprecipitation, Real-Time Polymerase Chain Reaction, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
